CENPE Promotes Glioblastomas Proliferation by Directly Binding to WEE1

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117417

Authors

Chuanling Ma

Jianchao Wang

Jie Zhou

Kaisen Liao

Min Yang

Fangqiong Li

Meng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma (GBM) is one of the most lethal tumors. Even though radiotherapy and chemotherapy have been greatly developed, the survival of patients with GBM is still only about 16 months.

Methods: In this assay, centromere protein E (CENPE) expression levels were measured using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot (WB) assays. 5-ethynyl-2'-deoxyuridine (EDU) assay was used to assess the effect of CENPE on cell proliferation. The propidium iodide (PI) method was used to detect the cell cycle.

Results: CENPE expression was increased in GBM tissues and was associated with clinical stage and unfavorable overall survival in glioma patients. Inhibition of CENPE expression resulted in proliferation inhibition of U251 and U87 cell. Cell cycle assay showed that CENPE mainly regulates the G0-G1 and G2/M phase transitions. Then, we found that CENPE regulated the proliferation of GBM mainly through WEE1 G2 checkpoint kinase (WEE1) pathway and can bind to WEE1.

Conclusions: CENPE promotes GBM proliferation through WEE1 pathway and binding to WEE1.

Citing Articles

E2F1-driven CENPM expression promotes glycolytic reprogramming and tumorigenicity in glioblastoma.

Yi Z, Jia Y, Lu R, Li C, Wen L, Yin X Cell Biol Toxicol. 2024; 41(1):4.

PMID: 39707034 PMC: 11662047. DOI: 10.1007/s10565-024-09945-7.

Analyzing the expression and clinical significance of CENPE in gastric cancer.

Wang J, Li X, Qiang X, Yin X, Guo L BMC Med Genomics. 2024; 17(1):119.

PMID: 38702677 PMC: 11067209. DOI: 10.1186/s12920-024-01887-7.

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity and .

Sharma S, Wang S, Yang W, Lin H, Lai M, Chen H J Med Chem. 2024; 67(4):2963-2985.

PMID: 38285511 PMC: 10895674. DOI: 10.1021/acs.jmedchem.3c02053.

CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma.

Wu H, Liu H, Zhang Z, Chen J Eur J Med Res. 2023; 28(1):481.

PMID: 37925501 PMC: 10625266. DOI: 10.1186/s40001-023-01449-0.

References

Hou S, Li N, Zhang Q, Li H, Wei X, Hao T . XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE. Cell Death Dis. 2016; 7(10):e2409. PMC: 5133980. DOI: 10.1038/cddis.2016.313. View

Roy D, Sheng G, Herve S, Carvalho E, Mahanty A, Yuan S . Interplay between cancer cell cycle and metabolism: Challenges, targets and therapeutic opportunities. Biomed Pharmacother. 2017; 89:288-296. DOI: 10.1016/j.biopha.2017.01.019. View

Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F, Sippl W . Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules. 2017; 22(12). PMC: 6149964. DOI: 10.3390/molecules22122045. View

Wu M, Li X, Liu Q, Xie Y, Yuan J, Wanggou S . miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1. Cancer Manag Res. 2019; 11:3099-3110. PMC: 6489667. DOI: 10.2147/CMAR.S192361. View

Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A . Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS One. 2013; 8(3):e56954. PMC: 3587640. DOI: 10.1371/journal.pone.0056954. View

Goncalves M, Hopkins B, Cantley L . Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med. 2018; 379(21):2052-2062. DOI: 10.1056/NEJMra1704560. View

Westphal M, Heese O, Steinbach J, Schnell O, Schackert G, Mehdorn M . A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015; 51(4):522-532. DOI: 10.1016/j.ejca.2014.12.019. View

Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders R . Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol. 2015; 33(30):3409-15. PMC: 4606059. DOI: 10.1200/JCO.2014.60.4009. View

Fantes P . Epistatic gene interactions in the control of division in fission yeast. Nature. 1979; 279(5712):428-30. DOI: 10.1038/279428a0. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S . Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients. Clin Cancer Res. 2018; 24(16):3820-3828. PMC: 6865048. DOI: 10.1158/1078-0432.CCR-17-3348. View

12.

Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L . Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010; 95(4):1708-16. DOI: 10.1210/jc.2009-1191. View

13.

Pinel S, Thomas N, Boura C, Barberi-Heyob M . Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment. Adv Drug Deliv Rev. 2018; 138:344-357. DOI: 10.1016/j.addr.2018.10.013. View

14.

Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View

15.

Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd M, Shumway S . Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012; 2(6):524-39. DOI: 10.1158/2159-8290.CD-11-0320. View

16.

Dun B, Sharma A, Xu H, Liu H, Bai S, Zeng L . Transcriptomic changes induced by mycophenolic acid in gastric cancer cells. Am J Transl Res. 2013; 6(1):28-42. PMC: 3853422. View

17.

Otto T, Sicinski P . Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017; 17(2):93-115. PMC: 5345933. DOI: 10.1038/nrc.2016.138. View

18.

Leijen S, van Geel R, Sonke G, de Jong D, Rosenberg E, Marchetti S . Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. J Clin Oncol. 2016; 34(36):4354-4361. DOI: 10.1200/JCO.2016.67.5942. View

19.

Nalepa G, Clapp D . Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018; 18(3):168-185. DOI: 10.1038/nrc.2017.116. View

20.

Balamuth N, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z . Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res. 2010; 70(7):2749-58. PMC: 2848992. DOI: 10.1158/0008-5472.CAN-09-3844. View